| |
Proportion appropriate tests
|
Difference in proportions
|
p value
|
|---|
|
CDSS arm
|
Control arm
|
|---|
|
Primary outcome (all tests)
|
0.58 (0.54–0.62)
|
0.38 (0.34–0.41)
|
0.21 (0.16–0.26)
|
< 0.0001
|
|
Subgroups per indication
|
|
Check-up
|
0.26 (0.24–0.28)
|
0.17 (0.16–0.19)
|
0.08 (0.06–0.11)
|
< 0.0001
|
|
Medication follow-up
|
0.78 (0.75–0.82)
|
0.74 (0.70–0.78)
|
0.04 (0.00–0.09)
|
0.0591
|
|
Cardiovascular disease management
|
0.41 (0.37–0.45)
|
0.30 (0.28–0.32)
|
0.11 (0.07–0.15)
|
< 0.0001
|
|
Hypertension
|
0.47 (0.43–0.50)
|
0.39 (0.35–0.42)
|
0.08 (0.03–0.12)
|
0.0007
|
|
Type 2 diabetes
|
0.51 (0.47–0.54)
|
0.38 (0.35–0.41)
|
0.13 (0.08–0.17)
|
< 0.0001
|
|
Fatigue
|
0.81 (0.79–0.83)
|
0.67 (0.64–0.70)
|
0.14 (0.10–0.17)
|
< 0.0001
|
|
Anemia
|
0.82 (0.81–0.84)
|
0.76 (0.74–0.78)
|
0.06 (0.03–0.09)
|
< 0.0001
|
|
Liver disease
|
0.56 (0.53–0.59)
|
0.43 (0.39–0.46)
|
0.13 (0.08–0.18)
|
< 0.0001
|
|
Gout
|
0.27 (0.23–0.31)
|
0.16 (0.14–0.18)
|
0.11 (0.06–0.16)
|
< 0.0001
|
|
Chronic kidney disease
|
0.66 (0.61–0.70)
|
0.51 (0.46–0.56)
|
0.14 (0.09–0.20)
|
< 0.0001
|
|
Acute coronary syndrome
|
0.06 (0.05–0.07)
|
0.04 (0.02–0.05)
|
0.02 (0.01–0.04)
|
0.0081
|
|
Lung embolisma
|
0.06 (0.02–0.10)
|
0.02 (0.01–0.04)
|
0.03 (− 0.01–0.08)
|
0.1608
|
|
Rheumatoid arthritis
|
0.79 (0.76–0.82)
|
0.61 (0.56–0.66)
|
0.18 (0.12–0.24)
|
< 0.0001
|
|
Thyroid disease
|
0.50 (0.47–0.54)
|
0.45 (0.42–0.49)
|
0.05 (0.01–0.09)
|
0.0136
|
|
Sexually transmitted infections
|
0.29 (0.23–0.36)
|
0.33 (0.27–0.39)
|
− 0.04 (− 0.13–0.06)
|
0.4719
|
|
Acute diarrhea
|
0.54 (0.46–0.62)
|
0.33 (0.28–0.38)
|
0.22 (0.10–0.33)
|
0.0002
|
|
Chronic diarrhea
|
0.41 (0.34–0.49)
|
0.25 (0.22–0.29)
|
0.16 (0.08–0.24)
|
0.0001
|
- CDSS clinical decision support system
- aNumbers do not include corrections for the laboratory and the number of study indications per panel
